+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?



A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?



Diabetes Care 36(7): 2118-2125



There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia. In addition, there are significant data with dipeptidyl peptidase 4 (DPP-4) inhibitors showing efficacy comparable to sulfonylureas but with weight neutral effects and reduced risk for hypoglycemia. However, over the recent past there have been concerns reported regarding the long-term consequences of using such therapies, and the issues raised are in regard to the potential of both classes to promote acute pancreatitis, to initiate histological changes suggesting chronic pancreatitis including associated preneoplastic lesions, and potentially, in the long run, pancreatic cancer. Other issues relate to a potential risk for the increase in thyroid cancer. There are clearly conflicting data that have been presented in preclinical studies and in epidemiologic studies. To provide an understanding of both sides of the argument, we provide a discussion of this topic as part of this two-part point-counterpoint narrative. In the point narrative below, Dr. Butler and colleagues provide their opinion and review of the data to date and that we need to reconsider the use of incretin-based therapies because of the growing concern of potential risk and based on a clearer understanding of the mechanism of action. In the counterpoint narrative following the contribution by Dr. Butler and colleagues, Dr. Nauck provides a defense of incretin-based therapies and that the benefits clearly outweigh any concern of risk.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036881076

Download citation: RISBibTeXText

PMID: 23645885

DOI: 10.2337/dc12-2713


Related references

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? How safe are the GLP-1-based therapies?. 2013

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? The benefits by far outweigh the potential risks. 2013

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 36(7): 2126-2132, 2014

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. Journal of the American Osteopathic Association 114(5 Suppl 2): S6-13, 2015

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Clinical and economic implications of incretin-based therapies. Endocrinology and Metabolism Clinics of North America 36 Suppl 2 Incretin: 18-26, 2008

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin-based therapies for type 2 diabetes: clinical utility. Endocrinology and Metabolism Clinics of North America 35 Suppl 1: 12-6; Discussion 17-19, 2007

Incretin-Based Therapies for Type 2 Diabetes: Clinical Utility. Endocrinology and Metabolism Clinics of North America 35: 12-16, 2006

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Efficacy and safety of incretin based therapies: clinical trial data. Journal of the American Pharmacists Association 49 Suppl 1: S30-S40, 2009